Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 6/20 | 0.35 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540327 | 1.00 | PDE5A (0.37) | PDE5ALCKFLT3PRKCQBCHE | |
| SCHEMBL3544405 | 0.91 | FLT3 (0.44) | PDE5ALCKFLT3 | |
| SCHEMBL3544404 | 0.91 | FLT3 (0.44) | PDE5ALCKFLT3 | |
| SCHEMBL3537416 | 0.90 | PDE5A (0.47) | PDE5ALCKFLT3BCHEACHE | |
| SCHEMBL3537419 | 0.90 | PDE5A (0.47) | PDE5ALCKFLT3BCHEACHE | |
| SCHEMBL3540564 | 0.88 | EGFR (0.38) | PDE5ALCKFLT3PRKCQBCHE | |
| SCHEMBL3540563 | 0.88 | EGFR (0.38) | PDE5ALCKFLT3PRKCQBCHE | |
| SCHEMBL13037017 | 0.88 | BCHE (0.38) | FLT3BCHEACHEGSK3BBACE1 | |
| SCHEMBL3535225 | 0.88 | TRIM58 (0.40) | FLT3 | |
| SCHEMBL3541535 | 0.88 | TRIM58 (0.43) | PDE5AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829566-B2 | Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | MEDERSKI WERNER | 2010-11-09 | — | — | US | disclosed |
| US-20070293667-A1 | 4-Amino-quinazolines | MEDERSKI WERNER | 2007-12-20 | — | — | US | disclosed |
| WO-2004030671-A2 | USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044204-A1 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044204-A1 | 4-amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | PDE5A 2590/4885LCK 2771/4885FLT3 493/4885 |
| US-20070293667-A1 | 4-Amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | PDE5A 2525/4885LCK 2507/4885FLT3 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.